ClinicalTrials.gg
CompletedNCT07847879Updated Nov 19, 2026

Effects of Pulmonary Rehabilitation Exercises in Patients With Axial Spondyloarthritis

An interventional study of Pulmonary Rehabilitation Program and Conventional Exercise Program in Axial Spondyloarthritis and Ankylosing Spondylitis (AS), sponsored by Sisli Hamidiye Etfal Training and Research Hospital. Completed at 1 site in Turkey (Türkiye). Open to participants aged 18 Years to 60 Years. Per ClinicalTrials.gov, last updated 2026-11-19.

Primary conditionSpondylitis, AnkylosingRegistry: Axial SpondyloarthritisReclassifiedWhy we changed it
Registry
Axial Spondyloarthritis — the first condition term the registry derived for this study.
ClinicalTrials.gg
Spondylitis, Ankylosing
Why
  1. The study's listed conditions name Spondylitis, Ankylosing, a narrower term within Axial Spondyloarthritis.
Confidence
High: the new condition is named in the study's own listed conditions. Of 351 hand-checked studies reclassified this way, 68% were exactly right and 84% in the right disease family; the registry's first term was right for 5% (measured 2026-10-21). How we classify →
Wrong?
Tell us the study's main condition →

Sponsored by Sisli Hamidiye Etfal Training and Research Hospital · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 10 months after the study started (first participant enrolled Nov 2025, registered Sep 2026).
Updated Nov 19, 2026Now CompletedNewly registeredGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
48
Allocation
Randomized
Ages
18 Years to 60 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-21

Among 84 studies in Spondylitis, Ankylosing with a site in Turkey — 19 open to participants now, 21 under way, none of them phase 3. Spondylitis, Ankylosing · Turkey.

Enrollment
37th of 49
48 · median 60
Started
2025
with 8 others
No phase
37 of 84
12 open now
Registered
80th of 84
by date

Among the 84 studies in Spondylitis, Ankylosing with a site in Turkey, this one is the 37th largest by enrollment of the 49 interventional ones that give a count, is one of 9 that started in 2025, is one of 37 with no phase, and was the 80th registered.

Spondylitis, Ankylosing

535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.

Browse Spondylitis, Ankylosing studies →

Open to participants now

19 of the 84 studies in Spondylitis, Ankylosing with a site in Turkey are open now. Recruiting first, the newest first:

14 more — sign in →

All 19 open studies →

A study can be open while its sites in Turkey have not opened yet or have stopped. Only those recruiting at a site in Turkey →

Who these studies take

Of the 63 Spondylitis, Ankylosing studies recruiting now, 24 (38%) set no upper age limit and 33 (52%) stop at 75 or younger; 10 take children under 18; 15 take healthy volunteers.

This study: 18 Years to 60 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 84 studies in Spondylitis, Ankylosing with a site in Turkey, or all of them as a file.
02

Study summary

This prospective, randomized, single-blind controlled study evaluates the effects of pulmonary rehabilitation exercises in patients with axial spondyloarthritis. Participants were randomized into two groups. The intervention group received a pulmonary rehabilitation program in addition to conventional exercises, while the control group received conventional exercises alone. The primary outcome was pain intensity assessed using the Visual Analog Scale (VAS). Additional assessments included exercise capacity, pulmonary function, disease activity, quality of life, spinal mobility, and chest expansion. Outcomes were evaluated at baseline, week 8, and week 12.

Read the detailed description

This is a single-center, prospective, randomized, single-blind controlled study conducted in patients with axial spondyloarthritis followed at the Physical Medicine and Rehabilitation Clinic of Sisli Hamidiye Etfal Training and Research Hospital.

Participants were randomized into two groups using the National Cancer Institute Clinical Trial Randomization Tool with the Maximally Tolerated Imbalance method. The intervention group received conventional exercises together with a structured pulmonary rehabilitation program. The pulmonary rehabilitation program included breathing exercises, range-of-motion exercises, aerobic exercise, and strengthening exercises.

Participants in the intervention group performed home-based range-of-motion and breathing exercises twice daily for 10 repetitions. Breathing exercises included pursed-lip breathing, diaphragmatic breathing, lateral abdominal breathing, relaxation and breathing control exercises, and neck and shoulder stretching exercises. In addition, participants completed supervised cycle ergometer exercise sessions at the hospital twice weekly for 8 weeks, with each session lasting approximately 30 minutes including warm-up and cool-down periods. Aerobic exercise intensity was prescribed at moderate intensity using the Karvonen method, with the Borg Rating of Perceived Exertion used when appropriate. Upper-extremity and shoulder-girdle strengthening exercises were also included.

The control group received a conventional exercise program.

The primary outcome was pain intensity measured using the Visual Analog Scale (VAS), with the primary endpoint defined as week 12. Secondary assessments included the Six-Minute Walk Test, Ankylosing Spondylitis Quality of Life Questionnaire, Maximum Voluntary Ventilation, pulmonary function tests, chest expansion, modified Schober distance, occiput-to-wall distance, lateral spinal flexion, Bath Ankylosing Spondylitis Disease Activity Index, and C-reactive protein. Assessments were performed at baseline, week 8, and week 12.

03

Conditions studied

  • Axial Spondyloarthritis
  • Ankylosing Spondylitis (AS)

Browse trials for

Keywords

  • Pulmonary Rehabilitation,
  • Respiratory Function
  • Quality of Life
  • Disease Activity
04

In context

Spondylitis, Ankylosing Reclassified

535 studies on the registry are indexed under Spondylitis, Ankylosing; 100 are open to participants now.

This study's enrollment of 48 is below the median of 87 across 304 interventional studies indexed under Spondylitis, Ankylosing.

Browse Spondylitis, Ankylosing studies →

Lead sponsor

Sisli Hamidiye Etfal Training and Research Hospital is the lead sponsor of 114 studies on the registry; 13 are open to participants now.

Compared within Spondylitis, Ankylosing, this study's primary condition as ClinicalTrials.gg classifies it; the registry's first condition term is Axial Spondyloarthritis. The counts are of registry records indexed under each term, refreshed daily. How we classify →

05

Who can participate

Ages eligible
18 Years to 60 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Age between 18 and 60 years.
  • Fulfillment of the Assessment of SpondyloArthritis international Society (ASAS) classification criteria for spondyloarthritis and/or diagnosis of ankylosing spondylitis according to the Modified New York criteria.
  • Willingness to participate in the study and provision of .

Exclusion criteria

Exclusion Criteria:

  • Presence of a respiratory or cardiovascular disease that may affect exercise capacity, including , asthma, cardiac arrhythmia, or heart failure.
  • Recent surgery that prevents participation in the exercise program.
  • Upper-extremity musculoskeletal injury or history of thoracic trauma that may interfere with the exercise program.
  • Chronic neuromuscular or musculoskeletal disease limiting upper-extremity function.
  • Obesity, , or epilepsy.
  • Pregnancy or breastfeeding.
  • Severe contractures or axial deformities, including chest deformity, advanced kyphosis greater than 40 degrees, scoliosis, or rotoscoliosis.
  • Neurological or psychiatric disorders, including ongoing depression, that may interfere with participation in the study.
Terms in these criteria, in plain language(3)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

COPD

Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

06

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Single (Outcomes assessor)
Enrollment
48 participants (actual)

Study arms

  • Experimental
    Pulmonary Rehabilitation Plus Conventional Exercise

    Participants received a structured pulmonary rehabilitation program in addition to conventional exercise for 8 weeks. The program included home-based breathing and range-of-motion exercises, supervised cycle ergometer exercise twice weekly, and upper-extremity and shoulder-girdle strengthening exercises.

    Behavioral: Pulmonary Rehabilitation Program · Behavioral: Conventional Exercise Program

  • Active comparator
    Conventional Exercise

    Participants performed a home-based conventional exercise program. Exercise instructions were provided by video recording, and participants attended face-to-face follow-up sessions once weekly.

    Behavioral: Conventional Exercise Program

Interventions

  • BehavioralPulmonary Rehabilitation Program

    The pulmonary rehabilitation program was administered for 8 weeks in addition to conventional exercise. Participants performed home-based breathing and range-of-motion exercises twice daily for 10 repetitions. Breathing exercises included pursed-lip breathing, diaphragmatic breathing, lateral abdominal breathing, relaxation and breathing control exercises, and neck and shoulder stretching. Participants also performed supervised cycle ergometer exercise twice weekly for 30 minutes per session, including warm-up and cool-down periods, together with upper-extremity and shoulder-girdle strengthening exercises.

  • BehavioralConventional Exercise Program

    Participants performed a home-based conventional exercise program. Exercise instructions were provided through a video recording, and participants attended face-to-face follow-up sessions once weekly.

07

What researchers measure

Primary outcomes

  1. Change in Pain Intensity Assessed by Visual Analog Scale (VAS)

    Pain intensity is assessed using a 0-10 cm Visual Analog Scale (VAS), where 0 indicates no pain and 10 indicates the worst imaginable pain. Changes from baseline are evaluated at Week 8 and Week 12, with Week 12 defined as the primary endpoint.

    Time frame: Baseline, Week 8, and Week 12

Secondary outcomes

  1. Change in 6-Minute Walk Distance (6MWD)

    Exercise capacity is assessed using the 6-Minute Walk Test (6MWT). The total distance walked during 6 minutes is recorded in meters. Changes from baseline are evaluated at Week 8 and Week 12. Higher walking distances indicate better functional exercise capacity.

    Time frame: Baseline, Week 8, and Week 12

  2. Change in Ankylosing Spondylitis Quality of Life (ASQoL) Score

    Disease-specific quality of life is assessed using the Ankylosing Spondylitis Quality of Life (ASQoL) questionnaire. The total score ranges from 0 to 18, with higher scores indicating poorer quality of life. Changes from baseline are evaluated at Week 8 and Week 12.

    Time frame: Baseline, Week 8, and Week 12

  3. Change in Maximum Voluntary Ventilation (MVV)

    Respiratory muscle performance is assessed using Maximum Voluntary Ventilation (MVV), expressed in liters per minute (L/min). Changes from baseline are evaluated at Week 8 and Week 12. Higher MVV values indicate greater maximal ventilatory capacity.

    Time frame: Baseline, Week 8, and Week 12

  4. Change in Forced Vital Capacity (FVC)

    Forced vital capacity (FVC) is assessed by spirometry and reported both as an absolute volume in liters (L) and as a percentage of the predicted value (% predicted). Changes from baseline are evaluated at Week 8 and Week 12. Higher values generally indicate greater ventilatory capacity.

    Time frame: Baseline, Week 8, and Week 12

  5. Change in Forced Expiratory Volume in One Second (FEV1)

    Forced expiratory volume in one second (FEV1) is assessed by spirometry and reported both as an absolute volume in liters (L) and as a percentage of the predicted value (% predicted). Changes from baseline are evaluated at Week 8 and Week 12. Higher values generally indicate better expiratory airflow and pulmonary function.

    Time frame: Baseline, Week 8, and Week 12

  6. Change in Forced Expiratory Volume in One Second to Forced Vital Capacity Ratio (FEV1/FVC)

    The Forced Expiratory Volume in One Second/Forced Vital Capacity (FEV1/FVC) ratio is assessed by spirometry and expressed as a percentage (%). Changes from baseline are evaluated at Week 8 and Week 12. The ratio represents the proportion of the forced vital capacity exhaled during the first second of forced expiration.

    Time frame: Baseline, Week 8, and Week 12

  7. Change in Peak Expiratory Flow (PEF)

    Peak expiratory flow (PEF) is assessed by spirometry and reported in liters per second (L/s) and as a percentage of the predicted value (% predicted). Changes from baseline are evaluated at Week 8 and Week 12. Higher values indicate greater maximal expiratory flow.

    Time frame: Baseline, Week 8, and Week 12

  8. Change in Chest Expansion

    Chest expansion is assessed as the difference between chest circumference during maximal inspiration and maximal expiration and is expressed in centimeters (cm). Changes from baseline are evaluated at Week 8 and Week 12. Higher values indicate greater thoracic mobility.

    Time frame: Baseline, Week 8, and Week 12

  9. Change in Modified Schober Test

    Lumbar spine mobility is assessed using the Modified Schober Test and is expressed in centimeters (cm). Changes from baseline are evaluated at Week 8 and Week 12. Higher values indicate greater lumbar flexion mobility.

    Time frame: Baseline, Week 8, and Week 12

  10. Change in Occiput-to-Wall Distance

    Postural and cervical spine mobility is assessed using the occiput-to-wall distance and is expressed in centimeters (cm). Changes from baseline are evaluated at Week 8 and Week 12. Lower values indicate better postural alignment and spinal mobility.

    Time frame: Baseline, Week 8, and Week 12

  11. Change in Lateral Spinal Flexion

    Spinal mobility is assessed using the lateral spinal flexion test and is expressed in centimeters (cm). Changes from baseline are evaluated at Week 8 and Week 12. Higher values indicate greater lateral spinal mobility.

    Time frame: Baseline, Week 8, and Week 12

  12. Change in Bath Ankylosing Spondylitis Disease Activity Index (BASDAI) Score

    Disease activity is assessed using the Bath Ankylosing Spondylitis Disease Activity Index (BASDAI). The total score ranges from 0 to 10, with higher scores indicating greater disease activity. Changes from baseline are evaluated at Week 8 and Week 12.

    Time frame: Baseline, Week 8, and Week 12

  13. Change in C-Reactive Protein (CRP) Level

    Systemic inflammation is assessed by serum C-reactive protein (CRP) level, expressed in milligrams per liter (mg/L). Changes from baseline are evaluated at Week 8 and Week 12. Higher CRP levels indicate greater systemic inflammation.

    Time frame: Baseline, Week 8, and Week 12

08

Study locations

1 site
09

References and documents

Individual participant data

Plan to share: No — Individual participant data (IPD) will not be shared because no data-sharing plan was specified in the study protocol or informed consent process.

No publications or documents are linked to this record.

10

Timeline

2 registry updates since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Nov 2025 to primary completion in Oct 2026, 11 months.

Of 62 non-industry interventional studies with no phase under Spondylitis, Ankylosing, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 7 and three quarters within 20. This study's 11 months is close to that.

Counting every sponsor, half of 65 studies reached it within 12 months; a quarter within 7 and three quarters within 20.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 22, 2026
First posted
Sep 29, 2026
StartActual
Nov 10, 2025
Primary completionActual
Oct 15, 2026
CompletionActual
Oct 15, 2026
Last update
Nov 19, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Active, not recruiting→Completed
changed Nov 19, 2026
Secondary outcomes
1 edited
What changed in the outcomes
  • ChangedBefore Change in FEV1/FVC RatioNow Change in Forced Expiratory Volume in One Second to Forced Vital Capacity Ratio (FEV1/FVC)Time frame: Baseline, Week 8, and Week 12
Nov 19, 2026
Registered
First appeared on the registry
Sep 29, 2026
Show all 2 updates
  1. Nov 19, 2026
    Active, not recruiting→Completed
    Secondary outcomes 1 edited
    What changed in the outcomes
    • ChangedBefore Change in FEV1/FVC RatioNow Change in Forced Expiratory Volume in One Second to Forced Vital Capacity Ratio (FEV1/FVC)Time frame: Baseline, Week 8, and Week 12
    + 3 other changes: verification date, date precision and description
  2. Sep 29, 2026
    First appeared on the registry

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

11

Registry details

Key details

Study ID
NCT07847879
Responsible party
Latif Tosun (Physical Medicine and Rehabilitation Resident, Sisli Hamidiye Etfal Training and Research Hospital) — Principal investigator
First posted
Sep 29, 2026
Start date
Nov 10, 2025
Primary completion
Oct 15, 2026
Completion
Oct 15, 2026
Last update
Nov 19, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Nov 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion